Kyverna Therapeutics(KYTX) - 2023 Q4 - Annual Results

Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results EMERYVILLE, Calif., March 26, 2024 – Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, today reported its business highlights and financial results for the full year ended December 31, 2023. "2023 was a momentous year for Kyverna as we brought KYV-101 into the clinic in both the U ...